Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

Do you routinely evaluate patients with collagen disorders or Ehlers-Danlos for platelet defects?

1
1 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester

Yes, I routinely carry out a full hemostasis evaluation, including platelet aggregation and release studies, in patients referred to me with easy bruising and hypermobility with an increased Beighton score suggesting EDS and in those already diagnosed genetically with EDS. EDS patients typically hav...

How do you approach treatment of a glioblastoma in pregnancy?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Louisville School of Medicine

Glioblastoma during pregnancy could be treated safely (to mother and fetus) with certain precautions and modifications. Collaboration and consultation with the patient’s obstetrician are essential. External shielding over the patient’s abdomen during treatment will decrease the external scatter radi...

What is your response to the question, "Is this terminal?"

18
8 Answers

Mednet Member
Mednet Member
Medical Oncology · Stanford University School of Medicine

Thanks for this question, it's really important. This question comes up in two distinct scenarios: when a person is first diagnosed and when a person is nearing the end of her life. Let's talk about them in sequence. 1). At diagnosis: When a person is first diagnosed, this question is part of "getti...

What are the best labs to trend improvement in HLH?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · UCSF Medical Center-Mission Bay

Unfortunately, there is not one specific laboratory test to definitively trend responses to HLH directed therapy. In general, our approach is to obtain baseline inflammatory labs including CBC with differential, ferritin, soluble IL2 receptor (sIL2r), triglycerides, coagulation studies (PT/PTT) incl...

How do you counsel patients and caregivers regarding management of cancer-associated cachexia?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Medical School

ASCO guidelines re: anorexia/cachexia were just published in May 2020. Basically, they note the magnitude of the clinical problem and the limited therapeutic options proven to be helpful. They state that dietician consultation is reasonable to employ. They also note that it is reasonable for a clini...

For iron deficiency anemia due to heavy menstrual bleeding, what is your preferred method of controlling heavy menses?

3 Answers

Mednet Member
Mednet Member
Hematology · The Mass General Porphyria Center

I definitely loop in my GYN friends for this one! According to ACOG: "Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life." The consequences of HMB are substantial and multifaceted, and, as we f...

What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?

5
2 Answers

Mednet Member
Mednet Member
Geriatric Medicine · Case Western Reserve University/University Hospitals Cleveland Medical Center

Hope for the miracle yourself! Broaden: “Are there any other things you are hoping for?” Hope for the best, prepare for the worst: “I see how much you want a miracle. I wonder if we can talk about what we should do if this doesn’t happen.” Consider involving a religious leader if relevant.

How should you manage a COVID-19 infected/suspected patient who is receiving chemotherapy and cannot interrupt or delay their cancer treatment?

8
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Fred Hutchinson Cancer Research Center

This is difficult to answer specifically without further details. There certainly is accumulating evidence that patients with cancer, especially those receiving immunosuppressive chemotherapy, are at greater risk of COVID-19 infection if exposed, and a greater risk of serious and life-threatening co...

For transplant-ineligible aplastic anemia planned for immunosuppression, how do you approach duration and tapering of cyclosporine and eltrombopag?

1 Answers

Mednet Member
Mednet Member
Hematology · Dana-Farber Cancer Institute

One of the most common mistakes in the management of AA is premature tapering of cyclosporine or tacrolimus. If there is a complete remission, and by that I mean normalization of counts, not complete remission as defined in some papers (e.g., ANC 1000, Plts 100,000, Hb 10 as in de Latour et al., PMI...

How do you present the trade off between a small chance of a sustained response for a new drug at the expense of potential worsening quality of life?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center

Since we now have an increasing number of treatments at our disposal, this becomes an ever more frequent conversation in oncology. This question gets at several Shared Decision Making (SDM) model steps. Usually in this scenario, there are not routine standard of care options and highlighting the pat...